[Hydroxyurea and HIV infection].
Hydroxyurea is an anticancerous product, used recently in the treatment of HIV-1 infection thanks to its inhibitory action in viral replication, potentialization of the nucleosides activity (particularly ddI or didanosine) and its cytostatic properties on CD4 and CD8 lymphocytes. Many studies showed its efficiency, as further drug, in initial regimen of a tritherapy (containing ddI) and salvage therapy. The dosage of 500 mg bid seems tolerated well by adults, and 20 mg/kg by children. Long-term tolerance remains unknown. With ddI, it could be proposed in developing countries.
Nkoghe
D
D
Service de Médecine interne, Université de Liège.
Kola
L
L
Léonard
P
P
Demonty
J
J
Moutschen
M
M
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D002648:Child; D016049:Didanosine / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D006918:Hydroxyurea / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D019384:Nucleic Acid Synthesis Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D019384:Nucleic Acid Synthesis Inhibitors; D016049:Didanosine; D006918:Hydroxyurea